Rockwell Medical Named 'Great Place to Work' for Third Year in a Row
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2025
0mins
Source: Businesswire
Great Place to Work Certification: Rockwell Medical, Inc. has been recognized as a Great Place to Work for the third consecutive year, reflecting its commitment to a high-trust workplace culture that values employee experience and innovation.
Company Overview: Rockwell Medical specializes in developing and distributing hemodialysis products, aiming to provide exceptional service and quality to dialysis clinics and improve the lives of patients with end-stage kidney disease.
Analyst Views on RMTI
Wall Street analysts forecast RMTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RMTI is 3.75 USD with a low forecast of 2.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.950
Low
2.50
Averages
3.75
High
5.00
Current: 0.950
Low
2.50
Averages
3.75
High
5.00
About RMTI
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
